Ku JC, Priola SM, Mathieu F, et al. - The risk-benefit profile of antiplatelet (AP) vs anticoagulant (AC) therapy in rates of ischemic stroke and hemorrhagic complications was compared in blunt cerebrovascular injuries (BCVIs) patients. From 2010 to 2015, researchers identified 2,044 BCVI patients, as described in the 22 studies from OVID Medline, Embase, Web of Science, and Cochrane Library databases in combination with their institutional data. Findings from this meta-analysis suggest similar effectiveness of AC vs AP in preventing ischemic stroke, however, the trauma population showed better tolerability towards AP. This indicates AP therapy to be a preferred option.